Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K38/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/011992IMMUNE AGONIST COMPLEX FOR TREATING ALZHEIMER'S DISEASE
WO 20.01.2022
Int.Class A61K 38/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Appl.No PCT/CN2020/141673 Applicant HANGZHOU XINGAO BIOTECHNOLOGY CO., LTD Inventor TAN, Xiangshi
Provided is an immune agonist complex for preventing or treating Alzheimer's disease or other neurodegenerative diseases, said immune agonist complex being composed of a brain metal ion homeostasis regulatory protein and transmembrane peptide fusion recombinant protein coupled liposome, and an innate immune agonist.
2.WO/2022/012067USE OF FIBROBLAST GROWTH FACTOR 6 IN PREPARATION OF MEDICINE FOR RELIEVING LIVER DAMAGE OF NON-ALCOHOLIC STEATOHEPATITIS
WO 20.01.2022
Int.Class A61K 38/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
18Growth factors; Growth regulators
Appl.No PCT/CN2021/080713 Applicant SHANGHAI PUDONG NEW AREA PEOPLE'S HOSPITAL Inventor WAN, Jian
Disclosed in the present invention is use of a fibroblast growth factor. The fibroblast growth factor is fibroblast growth factor 6, and the use is in the preparation of a medicine for relieving liver damage of non-alcoholic steatohepatitis.
3.WO/2022/015082THERAPEUTIC USE OF GLUCAGON DERIVATIVE OR CONJUGATE THEREOF FOR LIVER DISEASE
WO 20.01.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/KR2021/009124 Applicant HANMI PHARM. CO., LTD. Inventor KIM, Jung Kuk
The present invention relates to a therapeutic use of a glucagon derivative or a conjugate thereof for liver disease.
4.WO/2022/013221TREATMENT OF IMMUNE DEPRESSION
WO 20.01.2022
Int.Class A61K 38/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins
Appl.No PCT/EP2021/069463 Applicant TRANSGENE Inventor INCHAUSPE, Geneviève
The present invention is in the field of immunotherapy. The invention provides non- propagative viral vectors comprising a nucleic acid molecule encoding at least a polypeptide having an IL-7 activity, wherein said non-propagative viral vector is for use in the treatment of immune depression induced by sepsis, burn, trauma, major surgery, senescence and/or coronavirus.
5.WO/2022/015711FUSION PROTEINS OF ANTI-PD-L1 AND ATTENUATED INTERFERON, AND COMPOSITIONS AND THERAPEUTIC METHODS THEREOF
WO 20.01.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2021/041400 Applicant IMMUNE TARGETING INC. Inventor FU, Yang-Xin
The invention provides novel fusion proteins and therapeutic uses thereof. More particularly, the invention provides novel heterodimer fusion proteins of programmed death- ligand 1 (PD-L1) binding moiety and attenuated Interferon (IFN), e.g., Interferon-α (IFNα), Interferon-β (ΙFΝβ), or prodrugs thereof, and compositions and methods of preparation thereof, useful in treating various diseases and disorders (e.g., hyperplasia, solid tumor or hematopoietic malignancy).
6.WO/2022/013407THERAPEUTIC MICROBES
WO 20.01.2022
Int.Class A61K 35/66
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
Appl.No PCT/EP2021/069895 Applicant DANMARKS TEKNISKE UNIVERSITET Inventor BONGERS, Mareike
The invention relates to microbial cells and microbial cells for use as a medicament, the cells expressing a recombinant nucleic acid encoding a eukaryotic tyrosine hydroxylase. The cells produce L-DOPA and dopamine.
7.WO/2022/014697PEPTIDE, PEPTIDE SALT, PHARMACEUTICAL COMPOSITION AND BIOLOGICAL TISSUE CALCIFICATION INHIBITOR
WO 20.01.2022
Int.Class C07K 7/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
08having 12 to 20 amino acids
Appl.No PCT/JP2021/026751 Applicant HIROSHIMA UNIVERSITY Inventor YOSHIKO Yuji
Provided are a peptide or a salt thereof that are composed of an amino acid sequence represented by SEQ ID NO: 1, wherein said amino acid sequence lacks at least one of (a) the first aspartic acid residue and the second aspartic acid residue from the N-terminus and (b) the 17th glycine residue and the 18th aspartic acid residue from the N-terminus. The peptide or a salt thereof comprise an amino acid sequence represented by SEQ ID NO: 5, wherein the 6th aspartic acid residue from the N-terminus is substituted with another amino acid residue. In said peptide or a salt thereof, at least two of three specified serine residues contained therein are phosphorylated, and the peptide or a salt thereof exhibit an action that inhibits calcification of biological tissue.
8.WO/2022/015115THERAPEUTIC USE OF COMBINATION CONTAINING TRIPLE AGONISTIC LONG-ACTING CONJUGATE OR TRIPLE AGONIST
WO 20.01.2022
Int.Class A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Appl.No PCT/KR2021/009210 Applicant HANMI PHARM. CO., LTD. Inventor KIM, Jung Kuk
The present invention relates a therapeutic use of a combination containing a farnesoid X receptor agonist and a triple agonistic long-acting conjugate or a triple agonist, or a combination further containing an acetyl-CoA carboxylase inhibitor in addition to the above.
9.WO/2022/013269ENGINEERED PROBIOTIC BACTERIA FOR PREBIOTIC-RESPONSIVE CONTROL OF COLONIZATION
WO 20.01.2022
Int.Class C12P 19/02
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
02Monosaccharides
Appl.No PCT/EP2021/069555 Applicant DANMARKS TEKNISKE UNIVERSITET Inventor SARUP-LYTZEN, Kira
The invention provides a recombinant probiotic gram-negative bacterium engineered to grow on a rare carbohydrate as sole carbon source, and whose ability to colonize the mammalian gut is responsive to the supply of said carbohydrate. The invention further provides a pharmaceutical composition or kit comprising the recombinant probiotic gram-negative bacterium and said carbohydrate.
10.WO/2022/013554METHOD OF TREATMENT OF CONGENITAL MYASTHENIC SYNDROME USING DOK7 GENE OR POLYPEPTIDE
WO 20.01.2022
Int.Class A61K 31/137
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
135having aromatic rings, e.g. methadone
137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
Appl.No PCT/GB2021/051809 Applicant OXFORD UNIVERSITY INNOVATION LIMITED Inventor BEESON, David
The present invention relates to methods of preventing or treating a congenital myasthenic syndrome (CMS) in a subject, wherein the CMS is (a) congenital myasthenic syndrome associated with AChR deficiency or (b) fast-channel congenital myasthenic syndrome (FCCMS), the method comprising administering an effective amount of a DOK7 gene or a Dok-7 polypeptide, preferably a rAAV-DOK7 vector, to a subject in need thereof. The invention also relates to products for use in such methods.